

P1 Professor Dr Hasniza bt Zaman Huri, University Malaya
Unlocking the Vital Role of Pharmacists in Clinical Trials: Ensuring Safety and Patient Care

Presentation Synopsis: Pharmacist is a diverse healthcare profession and the role, especially in clinical trials have been demanding due to the rapid growth of innovator drugs worldwide. Clinical trials are the cornerstone of drug development, providing essential data to validate the efficacy and safety of new treatments. Within this complex ecosystem, pharmacists play a vital role in safeguarding patient well-being and optimizing trial outcomes. Pharmacists possess unique expertise in medication management, pharmacology and drug interactions, making them indispensable members of clinical trial teams. Today, the responsibilities of pharmacists extend beyond accountability of investigational products (IP). This talk will navigate the leading role of pharmacists in clinical trials to enhance the patient safety and providing optimum patient care in the quest for evidence-based healthcare innovation.

Brief CV: Professor Dr Hasniza Zaman Huri is the founder Dean of Faculty of Pharmacy, Universiti Malaya and a Professor of Clinical Pharmacy and Precision Medicine in the Department of Clinical Pharmacy and Pharmacy Practice. Professor Dr Hasniza is also an expert in clinical trial industry. She held various critical administrative posts, including the Manager of Clinical Investigation Centre (CIC), University Malaya Medical Centre from 2012-2015 and was later appointed as the Director of CIC (2015-2019). CIC, University Malaya Medical Centre is a world-class, reputable and multi-winning clinical trial centre. Under her tenure, CIC is awarded as the Best Clinical Trial Service Provider in Asia in 2013, 'the only Prime Site in the Asia Pacific region that has all new studies recruit the first patient within 100 days' in 2014, 7th position in the global, 3rd position in APAC and 1st position in Malaysia for IQVIA Prime Sites in 2017, Pfizer's INSPIRE (Investigator Networks, Site Partnerships and Infrastructure for Research Excellence) Site in Malaysia for 7 years consecutively and many more. She is also currently the Honorary Visiting Consultant at CIC and published more than 100 WOS journals in her area of expertise.

**SP1 Associate Prof Dr Adawiyah binti Jamil, Hospital Universiti Kebangsaan Malaysia
Herpes Zoster Vaccination in Adults: A Paradigm Shift with Shingrix**

Presentation Synopsis : This presentation will delve into the benefits of Shingrix vaccination, empowering healthcare professionals to effectively discuss shingles prevention with their patients. By understanding the impact of shingles and the efficacy of Shingrix, we can work towards a future where this painful condition is significantly less prevalent.

Brief CV : Senior Consultant Physician and Dermatologist in Hospital Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM UKM). She is currently the Head of Dermatology Unit in the Department of Medicine HCTM UKM. Her academic qualifications include MBCh BAO, MMed (Internal Med) and AdvMDerm. She was the Advanced Master of Dermatology (AdvMDerm, UKM) programme coordinator from 2010-2018 and has supervised the training of many AdvMDerm graduates and post-graduate students from other medical disciplines. Her areas of research interest are eczema, skin pH, moisturizer, photodermatology and nutrition.

Forum 1: Optimizing Healthcare Systems: Integrating Public and Private Sector Efforts to Improve Pharmacy Infrastructure and Services

Speakers:

1. Siti Nurul Fathihah binti Baharudin, Pharmacy Policy and Strategic Planning Division, Ministry of Health, Malaysia

Brief CV: Cik Siti Nurul Fathihah binti Baharudin is currently serving as the Senior Principal Assistant Director in the Pharmacy Policy Subdivision of the Pharmacy Policy and Strategic Planning Division at the Ministry of Health Malaysia. Cik Siti's career in pharmacy began in 2006 when she worked as a Provisionally Registered Pharmacist at Hospital Slim River, Perak. She became a Fully Registered Pharmacist in 2007, continuing her service at the same hospital until 2008. From 2008 to 2013, she served as a Fully Registered Pharmacist in the Pharmaceutical Services Division of the Ministry of Health Malaysia. Following this, she took on the role of Pharmacist in Charge at Seremban 2 Health Clinic in Negeri Sembilan from 2015 to 2016. She then worked in the Pharmacy Practice and Development Division from 2016 to 2023. Since 2023, she has been contributing her expertise to the Pharmacy Policy and Strategic Planning Division. Cik Siti holds a Bachelor of Pharmacy (Hons) from the International Islamic University Malaysia, earned between 2002 and 2006, and a Master in Pharmacy Practice from Universiti Teknologi MARA, completed between 2013 and 2015. Her professional interests and skills encompass quality use of medicines, policy development, drug information services, and patient education.

2. Chan Li Jin, Pharmaceutical Association of Malaysia (PhAMA), Malaysia

Brief CV: Chan Li Jin is the Executive Director of the Pharmaceutical Association of Malaysia (PhAMA), a non-governmental, non-profit, trade organization with 40 members mainly comprising iconic multinational pharmaceutical companies. A strong advocate for healthy living, she works closely with industry specialists, fellow advocates, patient groups and medical societies to expand Public-Private Partnerships and position the organization as a valuable partner and collaborator in the healthcare ecosystem. A communications specialist, she began her career as a Content Specialist, producing articles for major publications. Specialising in health and medical writing, she was inducted into advocacy, humanitarian work, social activism and community development and stays actively involved ever since. Passionate about life, death and everything in between, she strives to help people achieve their fullest potential by being a conduit to knowledge, networks and opportunities. She is currently an Executive Council Member of Arthritis Foundation Malaysia (AFM) and the Malaysian Menopause Society (MMS), and was inducted as Advisor to the Partners in Psoriatic Care (PPC) Coalition. She also sits in the Board of the Global Self Care Federation, and the Steering Committee of the Malaysian National Drug Policy (Dasar Ubat Negara).

3. Ng Li Ying, Malaysian Pharmacists Society, Malaysia

Brief CV: Ng Yi Ling is a dedicated community pharmacist currently serving as the Professional Care & Development Manager at Alpro Pharmacy Sdn Bhd since January 2024. She also holds the positions of Chairperson for the Safe Medicine Disposal Special Interest Group and Assistant Honorary Secretary I at the Malaysian Pharmacists Society. Previously, she worked at Caring Pharmacy Retail Management as Pharmacy Practice Manager, Assistant Pharmacy Practice Manager, Senior Pharmacy Practice Executive, and Provisional Registered Pharmacist. Yi Ling earned her Bachelor of Pharmacy from the International Medical University in 2018. Her expertise includes healthcare, project management, and event planning. She holds certifications such as Certified Smoking Cessation Service Provider and has received several honors and awards, including championing the MyPSA National Clinical Pharmacy Challenge in 2018.

**SPD1 Associate Prof Dr Adawiyah binti Jamil, Hospital Universiti Kebangsaan Malaysia
Look Beyond Ceramides in Sensitive Skin and Eczema**

Presentation Synopsis : Sensitive skin syndrome (SSS) is often self-diagnosed and may developed into eczematous skin if leave unmanaged. Cleanse, moisturize and protect routines are essential to manage both conditions with skin barrier repair and symptoms alleviation. Patient education on features and ingredients in skincare products with timely referrals to Dermatologists/GP are important to close the gap in disease management.

Brief CV : Senior Consultant Physician and Dermatologist in Hospital Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM UKM). She is currently the Head of Dermatology Unit in the Department of Medicine HCTM UKM. Her academic qualifications include MBCh BAO, MMed (Internal Med) and AdvMDerm. She was the Advanced Master of Dermatology (AdvMDerm, UKM) programme coordinator from 2010-2018 and has supervised the training of many AdvMDerm graduates and post-graduate students from other medical disciplines. Her areas of research interest are eczema, skin pH, moisturizer, photodermatology and nutrition.

**SPD1 Dr Benji Teoh Tze Yuen, Central Dermatology Specialist Clinic, Malaysia
Antibiotics in Acne: Can we do without them?**

Presentation Synopsis : The management of acne has traditionally relied heavily on the use of antibiotics due to their anti-inflammatory and antimicrobial properties. However, the rising concern over antibiotic resistance necessitates a reevaluation of their role as a primary treatment for acne. This presentation explores the potential of new-generation retinoids, particularly adapalene, as a cornerstone in acne management, thereby reducing the reliance on antibiotics. Adapalene, a third-generation synthetic retinoid, offers a favorable profile for treating acne. It modulates cell differentiation and keratinization, reducing comedogenesis and exhibiting potent anti-inflammatory effects. Unlike antibiotics, adapalene does not contribute to bacterial resistance, making it a sustainable long-term option. Its efficacy in both inflammatory and non-inflammatory acne lesions has been well-documented, positioning it as a versatile therapeutic agent. Current guidelines recommend combining retinoids with other non-antibiotic treatments, such as benzoyl peroxide, to enhance efficacy while mitigating resistance risks. This combination not only maximizes therapeutic outcomes but also leverages the complementary mechanisms of action, ensuring comprehensive acne management. This presentation will delve into the clinical evidence supporting adapalene's efficacy and safety, emphasizing its role in modern acne treatment protocols. We will discuss how incorporating adapalene can significantly diminish the necessity for antibiotics, addressing both dermatological and public health concerns. By focusing on adapalene and other retinoids, we can pioneer a shift towards more sustainable, effective, and resistance-free acne therapies. The goal is to highlight a balanced approach that ensures optimal patient outcomes while safeguarding antibiotic efficacy for future generations.

Brief CV : Dr. Benji is a Consultant Dermatologist with over 19 years of experience in both the medical and dermatology fields. Throughout his career, he has honed his expertise as a Consultant Dermatologist through positions at prestigious medical institutions, including Hospital Kuala Lumpur, Hospital Sultanah Aminah, and Hospital Selayang. Furthermore, he founded the Central Dermatology Specialist Clinic, a renowned name in the field. Additionally, he serves as a Sessional Dermatologist at Pantai Hospital Ampang and Park City Medical Center, further solidifying his reputation in the field. With his extensive experience and knowledge, he consistently delivers exceptional dermatological care to his patients. Dr. Benji has an impressive record of publications in esteemed journals. Additionally, he has actively engaged in sharing his expertise in dermatology through his participation as a speaker on various topics. Some of the

topics he has addressed include the impact of Psoriasis during the COVID-19 pandemic, the introduction of a novel understanding of the Pathogenesis of Atopic Dermatitis, and many others. Dr. Benji's contributions have been well-received and have enhanced the field.

**P3 Professor Dr Mohd bin Makmor Bakry, Universiti Kebangsaan Malaysia
Behaviour Driven Interventions in Digital Health Innovation**

Presentation Synopsis : The integration of digital based interventions into pharmacy services promises transformative benefits, revolutionizing patient care, improving outcomes, and enhancing operational efficiency. However, this transition is not without its challenges. From navigating privacy concerns to ensuring interoperability and user engagement, healthcare organizations must address a myriad of complexities to successfully adopt digital interventions. A 3-phase mixed-method approach was used to investigate the challenges in adopting health apps to enhance medication adherence among T2DM patients. The Phase 1 study revealed three primary themes that affect perceived usefulness namely medication-, patient-, and healthcare professional-related factors; Three key themes affecting perceived ease of use which include patient-, apps-, and family-related factors. Patients perceived that digital apps were only beneficial for individuals with poor adherence, complex medication regimen and forgetfulness issues. The Phase 2 study demonstrated that most of the participants (76%) were not ready to use medication management apps, and the elements that influenced readiness included convenience, perceived benefits, openness to new technologies and digital literacy. Perceived usefulness was influenced by age, healthcare professionals' influence and engagement, while perceived ease of use was influenced by age, app interface, digital literacy, and prior experience. Several significant barriers were also identified. The Phase 3 study elucidated possible strategies to enhance adoption of mobile apps. The suggested strategies include technological strategy, economic strategy, social strategy, behavioural strategy, and environmental strategy. In conclusion, more behavioural driven interventions are required to describe the importance for adopting the digital health innovation in enhancing the medication adherence.

Brief CV : Professor Dr. Mohd graduated with BPharm (Hons) from UKM, MCLinPharm from USM, and PhD (Medicine & Therapeutics) from University of Glasgow, Scotland. His areas of expertise include pharmaceutical care, clinical pharmacokinetics, and pharmacogenomics. Recipient of the 2017 Anugerah Akademik Negara, and Rethinking and Redesigning Higher Education Award by the Ministry of Higher Education. Pioneer in clinical pharmacy simulation education in Malaysia. Delivered more than 60 talks as keynote and plenary speakers in conferences. Lead research projects value at more than RM2 million and published more than 100 articles in high impact journals. Supervised more than 60 postgraduates. Members of significant national and international committees such as Asian Association of Schools of Pharmacy, Pharmacy Board of Malaysia, Drug Control Authority, and Council of Pharmacy Deans. Appointed as Visiting/Adjunct Professor for various international universities.

**P4 Associate Professor Dr Tin Fei Sim, Pharmaceutical Society of Australia
Pharmacy of the Future: Lessons from Australia**

Presentation Synopsis The aging population, emergence of the pandemic and the evolving health care systems around the world have led to a paradigm shift in pharmacy practice. The change in consumers' health seeking behaviour and the need to meet the growing demand and expectations of our patients have rapidly expanded the role of pharmacists. Pharmacists are medicine experts - from medicine dispensing and counselling, triage and referral, to complex medication management reviews, minor ailments and chronic disease management, pharmacists play an integral part in our health system through community pharmacies, hospitals, aged care facilities, general practice and health services. Evidence shows that pharmacist intervention can reduce unnecessary emergency department presentations and hospitalisations. Australian pharmacists have also emerged as a key immunisation workforce, making a positive impact on Australia's immunisation rate. Pharmacists can, and should be supported to practice to top of scope, for the benefit of our patients and health system. In this presentation, Fei will provide a deep dive into innovative Australian pharmacy practice, sharing experience from an international lens as we navigate through the evolution of pharmacy practice in Malaysia

Brief CV: A/Prof Fei Sim is the National President and Chair of the Pharmaceutical Society of Australia (PSA) Board, the first female, and the first from a diverse cultural background to be elected to this position. She is an Associate Professor in the Curtin Medical School at Curtin University, Western Australia. Fei holds a Doctoral degree in Pharmacy, is a practising pharmacist, a pharmacist immuniser and an Accredited Mental Health First Aid Instructor. Fei served as the Western Australia State President of the PSA between 2017-2021, before she was elected to serve on the national Board. Fei is the current Chair of the Australian Pharmacy Leaders Forum (APLF), an independent coalition of senior decision-makers from national pharmacy organisations who work together on issues of national importance to the pharmacy profession and the public. She was the inaugural Chair of the Contemporary Community Pharmacy Practice (CCPP) Communities of Specialty Interest, which is a forum to support collaboration, innovation and strategic progression of various practice areas in pharmacy. Fei is an appointed member of the Federal Government's National Women's Health Advisory Council of the Women's Health and Equity Section (Primary and Community Care Group), and serves as a Co-Chair of the Access, Care and Outcomes Sub-Committee of this Council. She also serves as a member on the Federal Government's Unleashing the Potential of Health Workforce (Scope of Practice) Review Expert Advisory Committee and the Strengthening Medicare Implementation Oversight Committee. She is a Fellow of the UK Higher Education Academy and a Fellow of the PSA, and a Graduate Member of the Australian Institute of Company Directors.

**SP2 Dr Wong Mun Hoe, Pantai Hospital Kuala Lumpur, Malaysia
Empowering Pharmacists in the Management of Kidney Disease**

Presentation Synopsis : The launch of the Pharmacy CKD Toolkit marks a significant milestone in the collaborative efforts of AstraZeneca, the Malaysian Pharmacists Society (MPS), and the International Pharmacy Federation (FIP) to combat chronic kidney disease (CKD). This toolkit aims to promote the earlier identification of at-risk individuals through comprehensive education and pre-screening programs tailored for pharmacists. It includes practical, practice-based tools designed to fit seamlessly into the day-to-day pharmacy workflow, such as eLearning modules, a CKD Risk Assessment Tool, and a Primary Care Referral Letter. The successful implementation of this toolkit is expected to improve patient outcomes, support the differentiation and growth of pharmacies, and strengthen connections within the local primary care provider community.

Brief CV : Dr Wong Mun Hoe is currently the Consultant Nephrologist and Physician in Pantai Hospital Kuala Lumpur and Pantai Hospital Klang. He graduated from the International Medical University in 2004 and pursued his Masters in Internal Medicine and Nephrology sub-specialty training at University Malaya. His fields of interests include chronic kidney disease, glomerulonephritis, medical education and have been involved in training and examining medical students, postgraduate students, nurses and paramedical staff in both government and private institutions. He has numerous publications in journals and books and participates actively in nephrology activities in Malaysia and across the globe. Besides running a busy clinical practice, he continues to give talks to general practitioners, paramedical staff around Malaysia regarding chronic kidney disease.

SP3 Dr Mimi Wong, Gleneagles Hospital Kuala Lumpur, Malaysia
Mild to moderate eczema - Is there something new?

Presentation Synopsis: Atopic dermatitis is a common condition that causes itchy, dry, and inflamed skin. It usually begins in childhood but can start at any age. Over the last decade, the incidence of atopic eczema has increased 2-3 times in children. It could affect the quality of life of patients if not treated adequately. A holistic approach to eczema management is imperative to manage the condition. Daily maintenance is as important as treatment to ensure skin barrier is strengthened and hydrated. Innovation in eczema management has seen significant strides. The addition of prebiotics in eczema skincare has shown promising results in rebalancing skin microbiome.

Brief CV : Dr Mimi Wong is a Consultant Paediatrician and Paediatric Dermatologist from Gleneagles Hospital Kuala Lumpur. She graduated from the International Medical University, Malaysia in 2006 and became a full-fledged Paediatrician in 2014. Dr Mimi completed 2 years of training in Paediatric Dermatology in the Kuala Lumpur Women and Children's Hospital before joining the Paediatric Dermatology fellowship at the Hospital for Sick Children offered by University of Toronto in Canada for a further 2 years. She has great passion in treating various skin, hair and nail conditions in paediatric population, ranging from newborns to teenagers.

SP4 Dr Afif Ashari, Institut Jantung Negara, Malaysia
Revolutionizing the Practical Approach for Better Patients' CV Outcomes

Presentation Synopsis : Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality worldwide, requiring innovative strategies for improved patient outcomes. This talk explores the pivotal role of effective communication in enhancing cardiovascular health. Emphasizing a patient-centered approach, it discusses how healthcare providers can empower patients through better conversations, promoting adherence to treatment plans, lifestyle changes, and early detection.

Brief CV: Dr Afif Ashari's expertise lies in interventional cardiology and cardiac imaging, currently practicing at the National Heart Institute in Kuala Lumpur, Malaysia. His educational background includes a Bachelor of Medicine and Surgery from Barts and the London School of Medicine and Dentistry, as well as Membership of the Royal College of Physicians (MRCPUK, London). His work experience spans various roles in cardiology and related fields in hospitals in the United Kingdom and Malaysia, including a Cardiac Magnetic Resonance (CMR) Fellowship at the Royal Brompton Hospital in London. Additionally, he has presented on cardiology-related topics at various conferences and possesses clinical skills and experience in areas such as cardiac MRI and cardiac CT in both local and international settings.

SPL1 Professor Dr Olivier Bruyère, University of Liège, Belgium
Paradigm Shift in Early-Stage Knee Osteoarthritis; Boosting Movement and Quality of Life

Presentation Synopsis : Osteoarthritis (OA) is a chronic joint condition causing significant disability and healthcare burden. Early intervention is crucial to halt disease progression and improve quality of life. Community pharmacists play a vital role in early identification, patient education, and OA management. Non-pharmacological strategies, such as weight management, physical therapy, and lifestyle changes, are foundational in managing OA. Pharmacological treatments complement these approaches by providing symptom relief and functional improvement. Among these treatments, Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOAs) are highlighted in guidelines for their efficacy and safety. Differentiating SYSADOAs and other treatments is crucial for optimal patient care. Community pharmacists' expertise in these options ensures tailored treatment plans, especially for early-stage knee osteoarthritis aiming to delay surgery and enhance quality of life. In conclusion, the burden of OA requires early and effective management. Community pharmacists, with their accessible healthcare role, are essential in guiding both non-pharmacological and pharmacological treatments to achieve the best patient outcomes. This presentation highlights the importance of early treatment and strategic use of SYSADOAs in OA management.

Brief CV : Professor Dr Olivier Bruyère is a renowned expert in Clinical Epidemiology, Public Health, and Health Economics, currently serving as a full professor at the University of Liège, Belgium. He holds a PhD in Public Health Sciences and a BSc in Physiotherapy and Rehabilitation, both from the University of Liège. At the University of Liège, Professor Bruyère is a Professor of Clinical Epidemiology and Geriatric Rehabilitation, and he heads the Research Unit in Public Health, Epidemiology, and Health Economics. Additionally, he serves as the Scientific Director of the WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing. Professor Bruyère is the Founder and CEO of SARQOL SRL and the CEO of the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). He also presides over the Belgian Ageing Muscle Society (BAMS) and serves as the General Secretary of the Belgian Bone Club (BBC). Furthermore, he is a board member of the International Osteoporosis Foundation (IOF). Since 2013, Professor Bruyère has been a member of the Royal Academy of Medicine of Belgium. He has an extensive publication record with 475 papers, an H-index of 76, and over 28,000 citations. He is the Editor-in-Chief of Archives of Public Health and holds editorial roles in several other prestigious journals. His contributions to the field have been recognized with numerous awards, including the IOF-ESCEO Pierre Meunier Young Scientist Award and the Olof Johnell Science Award.

**SPL2 Professr Ernest Choy, Cardiff University School of Medicine, United Kingdom
Pharmacists at the Helm: Striking the Balance in Osteoarthritis Management**

Presentation Synopsis : Osteoarthritis (OA) is a prevalent and debilitating condition characterized by the progressive degeneration of joint cartilage and underlying bone, often leading to chronic pain and reduced mobility. Inflammation plays a critical role in the pathophysiology of OA, contributing to the symptoms and progression of the disease. We will explore the latest guideline recommendations for OA management, emphasizing the importance of individualized treatment plans. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for their analgesic and anti-inflammatory properties; however, their use requires a careful balance between maximizing therapeutic benefits and minimizing potential risks. By understanding the nuanced risk-benefit profiles of NSAIDs, pharmacists can play a pivotal role in optimizing treatment outcomes for patients with OA, ensuring both efficacy and safety.

Brief CV : Professor Ernest Choy is Head of Rheumatology and Translational Research at the Division of Infection and Immunity and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre at Cardiff University School of Medicine, Cardiff, Wales, UK. He is also Honorary Consultant Rheumatologist at University Hospital of Wales and Clinical Lead of the Welsh Arthritis Research Network (WARN). Prof Choy chaired the EULAR Taskforce on developing recommendations for management and classification criteria for fibromyalgia in 2007 and currently a member of the EULAR Quality of Care Committee. Prof Choy has served as clinical expert to the National Institute for Clinical Excellence in the UK and many pharmaceutical companies. He has published widely on treatments for rheumatic diseases in major medical journals such as the New England Journal of Medicine and The Lancet.

SPL3 Dr Ahmad Najib bin Azmi, Prince Court Medical Centre, Malaysia
Breaking Boundaries: Are All Hepato-Protectants SAME?

Presentation Synopsis : Chronic Liver Disease (CLD), often known as the silent killer, is a progressive condition that often presents minimal symptoms until significant liver damage has occurred. This presentation will provide a comprehensive overview of CLD, highlighting its subtle yet critical symptoms, common signs, and the diagnostic tests essential for early detection. We will delve into the therapeutic roles of S-Adenosylmethionine (SAME), an important agent in managing CLD due to its antioxidant and anti-inflammatory properties that safeguard liver cells and enhance liver function. The crucial role of pharmacists in the management of CLD will be emphasized, focusing on patient education, medication adherence, and the monitoring of drug interactions and side effects. Case studies will be presented to illustrate the real-world effectiveness of SAME in improving liver function and patient outcomes, particularly among specific patient groups such as those with non-alcoholic fatty liver disease or cirrhosis. The presentation will also discuss the recommended uses of SAME, underscoring its importance in a comprehensive management plan for patients experiencing oxidative stress-related liver damage.

Brief CV : Dr. Ahmad, an esteemed Consultant Physician and Gastroenterologist at Prince Court Medical Centre, holds an MBBS from IIUM, a Master's in Internal Medicine from UM, and a Gastroenterology & Hepatology Fellowship from UM. He has been actively involved in teaching since 2011, starting as a lecturer at USIM and becoming an Associate Professor in Medicine in 2015. Since 2018, he has continued to serve as an internal medicine visiting lecturer at USIM. He is also actively involved in article reviews and book publications, national and international consultations, and has received numerous awards for his contributions to the field.

SB1 Dr Wong Hui Tong, Sunway Medical Centre Innovative Approaches to Controlling Allergic Rhinitis

Presentation Synopsis: Allergic rhinitis, a common condition, can significantly impact our patients' quality of life if not managed effectively. The latest ARIA 2020 guidelines highlight antihistamines as a key treatment option, with recommendations assessed through visual analogue scores. To personalize treatment, patient profiling tools can help tailor antihistamine selection for optimal outcomes. Clarityne, a trusted brand with a long heritage, offers multiple innovative non-drowsy allergy solutions for patients and their families, relieving their allergies from over 200 indoor and outdoor allergens. Innovator Clarityne antihistamine provides superior dissolution and bioavailability compared to generic loratadine, ensuring more effective relief. Moreover, Clarinase Repetabs and Clarinase 24-hour formulations significantly enhance nasal airflow, providing additional benefits. For those not responding to pharmacological treatments, cutting-edge surgical options can be explored, offering hope for comprehensive relief from symptoms. By integrating these innovative strategies, we can significantly improve the management of allergic rhinitis and enhance patients' lives.

Brief CV: Dr. Wong Hui Tong is a Consultant ENT at Sunway Medical Centre. With extensive experience in ENT and Head and Neck Surgery, Dr. Wong holds fellowships in Rhinology and Skull Base Surgery from Switzerland & University Malaya, and fellowships in Rhinology (Advanced Sinus Surgical Technique) in Australia. Additionally, Dr Wong also acquired the International Nose Professional Training Programme in Korea. Dr. Wong moderates dissection surgery courses and medical symposiums, and is active in public health advocacy through appearances on Astro TV, newspaper columns, and social media. He also contributes to prestigious publications, including the New England Journal of Medicine.

SB2 Dr Ronnie Lim Jian Chen, Hospital Sultan Idris Shah, Malaysia
How did ARNI Pushed the Frontiers with RAAS Inhibition in CHF?

Presentation Synopsis: Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high prevalence, it is a major health and economic burden worldwide. Several mechanisms are involved in the pathophysiology of HF. First, the renin-angiotensin-aldosterone system (RAAS) is over-activated, causing vasoconstriction, hypertension, elevated aldosterone levels and sympathetic tone, and eventually cardiac remodeling. Second, an endogenous compensatory mechanism, the natriuretic peptide (NP) system is also activated, albeit insufficiently to counteract the RAAS effects. Since NPs are degraded by the enzyme neprilysin, it was hypothesized that its inhibition could be an important therapeutic target in HF. Sacubitril/valsartan is the first of the class of dual neprilysin and angiotensin receptor inhibitors (ARNI). In patients with HFrEF, treatment with ARNI has demonstrated to significantly reduce mortality and the rates of hospitalization and rehospitalization for HF when compared to enalapril. This session discusses in detail the demonstrated benefits of ARNI in the treatment of patients with HFrEF, including reduction of mortality and disease progression as well as improvement in cardiac remodeling. The review of this evidence, together with the recommendations of the latest clinical guidelines, position ARNI as a fundamental pillar in the treatment of patients with HFrEF.

Brief CV: A Malaysian-based, board certified interventional cardiologist and internal medicine specialist, who has served in various government hospitals with high patient load. Strives to provide the best possible outcomes for the patients by embracing new technology and techniques in the ever-evolving field of internal medicine and cardiology. A firm believer of evidence-based medicine, who also perceives medicine as an art which needs to be patient centric and holistic.

**SB3 Professor Dr Rosmawati binti Mohamed, University Malaya Medical Centre, Malaysia
Navigating the Double Burden of Fatty Liver Disease in T2DM**

Presentation Synopsis : Non-alcoholic fatty liver disease (NAFLD) has emerged as a common comorbidity in T2DM patients, presenting a "double burden" that complicates management and prognosis. This presentation aims to elucidate the pathophysiological connections between T2DM and NAFLD, explore current diagnostic and therapeutic strategies, and propose an integrated management approach to mitigate the double burden on patients.

Brief CV : Professor Dr Rosmawati Mohamed is a Consultant Hepatologist at the University Malaya Medical Centre, Kuala Lumpur. Internationally, she was appointed as Founding Co-chairperson of the WHO Strategic and Technical Advisory Committee for Viral Hepatitis both at the global level and at the Western Pacific Region, Co-chairperson and Founding Committee Member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific. Locally, she is the Master, Academy of Medicine of Malaysia (AMM) and serves in various committee of the Malaysian Medical Council governing medical specialists recognition, training and continuous professional development. She has worked tirelessly as a hepatitis and cancer advocate and organised nationwide campaigns on World Hepatitis Day and World Hepatitis Day together with MOH specialists, Malaysian Oncological Society and NGOs to increase public awareness on hepatitis and liver cancer.

**SB4 Dr Noor Shaheeran binti Abdul Hayi, Sophea Fertility Centre, Malaysia
Revolutionising Hormonal Contraception**

Presentation Synopsis : Nearly half of all pregnancies are unintended and unintended pregnancies can lead to various complications. One way to overcome unintended pregnancies is via contraception and hormonal contraceptives are the most common modern contraceptive method. There are various hormonal contraceptives available, and patients can choose based on their preference and lifestyle. Oral hormonal contraceptives are the most popular in Malaysia. However, compliance towards this oral method can hinder their effectiveness. We will look into an innovative hormonal contraceptive method that will address this compliance issue. So patients will have an alternative choice that they can consider when choosing the right contraceptive method for their personal use.

Brief CV : Dr. Noor Shaheeran is an Obstetrician & Gynaecologist based at Sophea Fertility Centre, who has more than 12 years' experience. She completed her medical degree from USM in 2004, subsequently the MRCOG from Royal College of Obstetricians and Gynaecologists, London, UK in 2011. She also completed her fellowship in reproductive medicine in 2023. Dr. Noor Shaheeran specialized in providing care for women's reproductive health, pregnancy and childbirth as well as offering guidance on family planning. At the same time, Dr. Noor Shaheeran is also a visiting consultant at Hospital Damai Jalan Ipoh and Ampang Puteri Specialist Hospital.

BL1 Khor Xin Yun, National Kidney Foundation Entrepreneurial Transformation: Leading Change in Healthcare Leadership

Presentation Synopsis: This presentation offers a comprehensive exploration of entrepreneurial leadership within the healthcare sector, chronicling the journey of a former ward pharmacist turned CEO of a digital health company and then, the CEO of one of the largest NGO in Malaysia. Xin Yun will delve into pivotal experiences and strategies that have shaped her leadership approach, driving impactful changes across diverse healthcare landscapes. Attendees will gain valuable insights into the multifaceted realm of innovation, spanning from pioneering product development to service enhancements aimed at optimizing patient care while simultaneously driving cost efficiencies. The session will also spotlight the strategic imperatives of marketing, funding sustainability, and the critical role of digital transformation in modernizing healthcare delivery systems. Moreover, the presentation will elucidate the significance of fostering human capital and nurturing leadership potential within healthcare organization to drive innovation. This presentation offering attendees valuable insights and practical experiences for navigating the ever-evolving challenges and opportunities within the healthcare sector.

Brief CV: Ms Khor Xin Yun is a healthcare leader with vast experience in various sectors within the healthcare industry and an excellent track record in spearheading digitalization and transformation in her previous and current works. Currently, she is the CEO of the National Kidney Foundation of Malaysia. Driven by her passion for digital health, NCD care, and preventive care, she strives to lead the team at NKF Malaysia toward greater innovation and digitalization in kidney care and prevention. Xin Yun is also set to share her wealth of knowledge and experiences gained to help the organisation grow and operate more efficiently and effectively. Prior to her appointment at NKF, she served as the Head of Digital Health for the Better Health Programme (BHP) Malaysia, funded by the United Kingdom Foreign, Commonwealth, and Development Office's Prosperity Fund. Born and raised in Penang, her passion and capabilities were further solidified in her previous post as Chief Executive Officer of Walnut Wellness, a home-grown healthcare company that leverages digital technology, new service design, and community networks to deliver effective preventive care. With a master's degree in Business Administration (MBA) and a bachelor's degree in Pharmacy, Xin Yun has also worked with the Ministry of Health Malaysia. There, Xin Yun gained clinical experience as a ward pharmacist and was also actively involved in the pharmaceutical sector's strategic planning and policy development areas.

BL2 Dr Dang Chee Chean, Hospital Malacca

Novel Therapeutic targeting of TP53-mutated Acute Myeloid Leukemia: Advances in Treatment

Presentation Synopsis : Acute myeloid leukemia (AML) with TP53 mutation is one of the most lethal cancers and portends an extremely poor prognosis. Based on in silico analyses of druggable genes and differential gene expression in TP53 mutated AML, we identified polo-like kinase 4 (PLK4) as a novel therapeutic target and examined its expression, regulation, pathogenetic mechanisms and therapeutic potential in TP53 mutated AML. PLK4 expression was suppressed by activated p53 signaling in TP53 wildtype AML and was increased in TP53 mutated AML cell lines and primary samples. Short-term PLK4 inhibition induced DNA damage and apoptosis in TP53 wildtype AML. Prolonged PLK4 inhibition suppressed the growth of TP53 mutated AML and was associated with DNA damage, apoptosis, senescence, polyploidy and defective cytokinesis. In TP53 mutated AML, cGAS-STING pathway was activated leading to secretion of cytokines and chemokines and activation of macrophages and T cells upon co-culture with AML cells. In vivo, PLK4 inhibition also induced cytokine and chemokine expression in mouse recipients and its combination with anti-CD47 antibody, which inhibited the "don't-eat-me" signal in macrophages, synergistically reduced leukemic burden and prolonged animal survival. The study shed important light on the pathogenetic role of PLK4 and might lead to novel therapeutic strategies in TP53 mutated AML.

Brief CV : Dr. Dang received his Bachelor of Pharmacy from UKM in 2006, followed by a Master in Clinical Pharmacy (Oncology) from USM in 2016. His strong interest in the oncology field drove him to pursue a PhD (Pharmacology in Oncology) from The University of Hong Kong in 2022. He has over 14 years of experience as an oncology pharmacist and is currently serving as the Head of Manufacturing Unit, Hospital Melaka. He is frequently invited to speak at various events to share his expertise in oncology pharmaceutical care and research. In 2024, he was appointed as the chairperson of the Clinical Pharmacy Working Committee (Oncology Pharmacy Specialty) and member of Pharmacy Research and Development Committee under the Pharmaceutical Services Programme, MOH Malaysia. He has made valuable contribution in development of the Malaysia Clinical Practice Guideline in Diagnosis and Management of Myeloproliferative Neoplasm, Management of Breast Cancer and the Cancer Drug Counselling: A Guide for Pharmacists. He is passionate about oncology-related research and has presented his research in numerous local as well as international conferences. In recognition of his monumental research work, he won the Best Abstract Award for his oral presentation at the 26th Medical Research Conference, Hong Kong and emerged as the recipient of the Outstanding Poster Award for his poster presentation at the 26th Research Postgraduate Symposium, The University of Hong Kong (HKU). He has also served as reviewer for several scientific journals and healthcare bodies besides actively involved as a study coordinator of several industry initiated clinical trials.

SB5 Alex Lai Xiao Yuan, Unifi Business, Malaysia
e-Pharmacy: Technology's Role in Your Pharmacy Practice

Presentation Synopsis : e-Pharmacy is a digital healthcare platform that allows you to connect with your patients and other healthcare practitioners, providing more accessible and personalised care to your patients. By transforming your pharmacy with technology, you would be able to create more opportunities to provide quality services as well as achieve better customer experience at your pharmacy, driving your pharmacy's growth and sustainability. Unifi Business offers the first and only complete solution bundle with e-Pharmacy solution, together with a government grant to support your digital transformation journey.

Brief CV : Alex has over 10 years of experience in solution consultancy and product management, having been in charge of a diverse range of technological fields from Connectivity, Data Centre, Cloud Computing to Cybersecurity; notably involved in Telekom Malaysia's Twin Core Data Centres and Cloud Alpha Edge, the latter being the sole Malaysian-owned Cloud infrastructure and platform. He is an advocate for all things digital and how technology can be applied to ease our everyday lives as well as to help us achieve more. He is currently the Head of Solution & Product Design at Unifi Business, leading the design and development of new and innovative Digital Solutions to help MSME (Micro, Small and Medium Enterprises) in embracing the digital economy. The Digital Solutions that are under Alex's purview includes, Unifi Cloud Storage, Small Office Security, SMART Internet (a variant of SDWAN), and also the newly launched e-Pharmacy; e-Pharmacy is a digital healthcare platform that allows pharmacists to connect with patients and other healthcare practitioners, providing more accessible and personalised care to patients. Alex holds a Master's Degree in Electronic Engineering and Computer Science from Université de Lorraine, France. His credentials include; Accredited Tier Designer (ATD), Accredited Tier Specialist (ATS), Accredited Operations Specialist (AOS), Certified TIA-942 Design Consultant (CTDC), Huawei Certified ICT Associate (HCIA), and Certified Human Resource Manager (CHRM).

BL3 Preethi Raghavan, Hospital Sungai Buloh
Current and Evolving Pharmacotherapies in HIV Care

Presentation Synopsis : The presentation will delve into the evolution of antiretrovirals, updated guidelines and the use of dolutegravir in various scenarios. It will also cover on pre-exposure prophylaxis and innovations in delivery methods, showcasing advances in HIV treatment and prevention strategies.

Brief CV Preethi Raghavan is a credentialed retroviral disease pharmacist by the Ministry of Health Malaysia and has been running the Medication Therapy Adherence clinic for Retroviral Disease (RVD) for the past 11 years. She is extensively involved as a RVD Preceptor in training pharmacist and building clinical knowledge as well as skills in retroviral disease for the state and country. She also actively conducts teaching sessions for nurses and doctors in the country. Preethi is dedicated to improving medication management especially among HIV- infected patients by her active involvement with the infectious disease team and in conducting various research. Preethi graduated with her Bachelor of Pharmacy (Hons) from University Science Malaysia in 2008 and Masters in Pharmacy Practice in 2020. One of her notable research , Impact of Point-Of-Care Pharmacist Counselling in Late Refills of ART, a study following the early warning indicators of World Health Organization was presented in London at the International AIDS Impact Conference 2019 and now has been established as part of the clinic/outpatient pharmacy protocol of the National Referral Center for Infectious Disease in Malaysia. She was also a board member of the RVD Sub-Committee at Pharmacy Services, Ministry of Health from 2016 to 2023 as well as one of the authors for the latest Malaysian Consensus Guidelines on Antiretroviral Therapy 2022.

SB6 Gina Koay Wan Lee, City Wellness Pharmacy
The Ubiquinol Frontier: Innovations and Insights for Pharmacists

Presentation Synopsis: In this presentation, award-winning Pharmacist, Gina Koay, will delve into the evidence-based and clinical impact of the body's primary fuel ATP production and potent antioxidant ubiquinol and its profound impact on cardiovascular health, fertility support, energy metabolism and antioxidant defence. Join Gina Koay in uncovering the transformative potential of ubiquinol supplementation for pharmacists. Explore its mode of action and pharmacological benefits while learning how to enhance patient care with Kaneka Ubiquinol™. Gain insights to revolutionize your practice by promoting holistic well-being in this dynamic session and reshape your approach as a pharmacist. Supported by 90+ clinical studies and 45+ years of research, Kaneka Ubiquinol™ is an evidence-based supplement recommended by healthcare practitioners to support multiple health conditions such as a healthy heart and vascular system, healthy LDL cholesterol levels in healthy people, healthy male and female fertility, cognitive function, energy production, fatigue, migraines, inflammation and optimal wellbeing. Kaneka Ubiquinol™ has been voted 'The Champion Ingredient' by China's mega e-commerce platform, Alibaba for 2023/24 and FFWS Annual Ingredients Cardiovascular Health Award 2024. Learning outcomes 1. Explore the primary advantages of Ubiquinol and best practices for prescribing it alongside statins and differentiate between Ubiquinol and ubiquinone within the human organism. 2. Understand the scientific basis of ubiquinol and its clinical application in cardiovascular health, fertility support, energy metabolism, and antioxidant defence. 3. Understand the precision manufacturing quality, stability, safety and efficacy of Kaneka Ubiquinol™.

Brief CV: Gina Koay, Founder and Managing Director of City Wellness Pharmacy, Malaysia, is a distinguished figure in the pharmaceutical industry. Recognized with the FAPA Community Pharmacy Section Award in 2023, she leads a community-based retail pharmacy committed to excellence since 2007. With a Bachelor of Pharmacy from Curtin University, Australia, and additional certifications in Evidence-based Complementary Medicine and Integrative Nutrition Health Coaching, Gina is a versatile professional. Elected as a council member of the Malaysian Pharmacists Society and holding leadership roles in various committees and organizations, she continues to make impactful contributions to the field. Currently appointed as an Advisory Board Member for Pharmacy Board Malaysia, Gina remains a vital force in shaping the industry's future.

BL4 Pang Kim Sun, Zuellig Pharma
Introducing eZR^x+ Empowering Asia's Pharmacies and Clinics for Success

Presentation Synopsis : eZR^x+ your one-stop order platform for streamlined healthcare purchasing. Simplify and seamlessly manage your medication purchasing process with a user-friendly interface and intuitive features available on web and mobile. Embrace digital transformation to optimize operations and stay ahead of the competition.

Brief CV : Kim-Sun Pang has been a part of Zuellig Pharma for nearly two decades, showcasing adaptability and innovation throughout his tenure. Notably, he led the digital transformation process during the pandemic, simplifying operations and empowering stakeholders through self-service platforms. Now, in an expanded role encompassing government affairs, corporate communications, and sustainability, Kim-Sun emphasizes a holistic approach to organizational development. As Director of Client Services, KAM, and Corporate Affairs, Kim-Sun oversees critical operations and maintains key client relationships within Zuellig Pharma. His strategic management extends to major healthcare clients, reflecting his deep understanding of industry dynamics. With a background in Biochemistry and a diverse skill set, including proficiency in supply chain management, Kim-Sun remains committed to excellence as he integrates government affairs and sustainability into his portfolio, driving forward-thinking initiatives in the pharmaceutical landscape.

BL5 Dr Hung-Chang Chou, Tajen University, Taiwan Novel Protein-Coated Nano Delivery System

Presentation Synopsis : The scientific community has shown significant interest in Bovine Serum Albumin (BSA) due to its biocompatibility, biodegradability, non-toxicity, cost-effectiveness, and excellent water solubility. Additionally, BSA possesses diverse functional groups such as hydroxyl, carboxyl, and thiol groups, making it an ideal candidate for drug delivery systems. This study aims to utilize the nanoprecipitation method for developing silica nanoparticles with dual thiol and amine functionalities and subsequently coating them with BSA to create an innovative carrier system. The nanoprecipitation method involved the synthesis of nanoparticles followed by their surface coating with BSA. Initially, 3-mercaptopropyl and 3-aminopropyltrimethoxysilane were dissolved in dimethyl sulfoxide for acid-induced condensation, forming the organic phase. This organic phase was then injected into the aqueous phase, resulting in the formation of silica nanoparticles with dual thiol and amine functionalities. The positively charged characteristics of the nanoparticle surface facilitated self-assembly with BSA, leading to the formation of BSA-coated nanoparticles. The prepared nanoparticles exhibited a spherical structure, with varying physical properties depending on the concentration of BSA coating. The average particle size ranged from 212.1 ± 44.2 nm to 1760.1 ± 1291.7 nm, and the zeta potential ranged from -17.5 ± 1.8 mV to 42.6 ± 2.9 mV. Larger particle sizes in the micrometer range were observed as the zeta potential approached zero. Additionally, the BSA-coated nanoparticles demonstrated strong anti-aggregation properties post-lyophilization. These results underscore the potential of BSA as a protective agent and highlight the controllable nature of nanoparticle size and aggregation by modulating their surface properties.

Brief CV : Dr. Chou received his pharmacy and master degree from National Defense Medical Center in Taipei, Taiwan and his PhD in Pharmaceutics from Taipei Medical University in the same city. He holds the position of assistant professor in the Department of Pharmacy and Master Program at the College of Pharmacy and Health Care, Tajen University from 2022. His research interests have focused on the nano delivery system and its applications. His publications include 9 peer-reviewed articles in pharmaceutics and pharmacokinetics. Dr. Chou's research is focused on the development and clinical application of nanocarriers. By using appropriate materials, they investigate nanoparticles both in vitro and in vivo. Their goal is presenting the effect of surface properties on the cellular interaction. Moreover, by avoiding the cellular uptake/first-pass by the liver, they attempt to enhance the efficiency of drug delivery to human bodies. They cooperate with Dr. Lin Cheng-Han, Tri-Service General Hospital Songshan Branch, in this project. Besides to the nanocarriers, they have an Artificial Intelligence (AI) project with Department of Pharmacy, Kaohsiung Veterans General Hospital. This project is attempting to develop and implement the machines to educate the patients or answer the patients' questions.

**BL6 Dr Navin Kumar Loganadan, Hospital Putrajaya
Specialising as a Diabetes Pharmacist: What is the pathway?**

Presentation Synopsis : Clinical pharmacy services involve pharmaceutical care by pharmacists to optimize patients' treatment outcomes. In Malaysia, clinical pharmacy services began about two decades ago through pharmacokinetic and parenteral nutrition services whereby the inputs by pharmacists were paramount in patient management. The Diabetes Medication Therapy Adherence Clinic (DMTAC) service began in 2006 and is now available in over 400 facilities (hospitals and health clinics) within MOH. DMTAC aims to improve the knowledge and adherence of diabetes patients to medication therapy and improve glycemic control. In DMTAC, diabetes patients receive medication knowledge assessment, medication adherence assessment, insulin injection technique assessment, hypoglycemia assessment, review of self-monitoring of blood glucose (SMBG) readings, monitoring of medication side effects, and adjustment of insulin doses during scheduled pharmacist follow-ups. Besides, diabetes education is provided using the DMTAC education modules during each clinic visit. DMTAC pharmacists work in the diabetes care team comprising clinicians, dietitians, diabetes care nurses and physiotherapists. Many studies conducted on DMTAC patients have demonstrated significant improvements in medication adherence, injection technique and glycemic control. The DMTAC training has also evolved over the years starting from a 3 weeks training module in 2006 to a 6-month comprehensive training module introduced in 2021. Moving forward, certified DMTAC pharmacists may undertake intermediate and advanced training to further specialize in this field through a one-year training programme which would further solidify their role in diabetes management. In summary, pharmacists in Malaysia have established their role in diabetes patient care.

Brief CV : Dr. Navin Kumar Loganadan is currently the Head of Specialist Clinic Pharmacy & DMTAC Services at the Endocrine Institute, Putrajaya Hospital in Putrajaya, Malaysia. Dr. Navin has 16 years of experience as a Diabetes Care Clinical Pharmacist in the Diabetes Medication Therapy Adherence Clinic (DMTAC) in the Ministry of Health, Malaysia. He is currently the Chairman of the Diabetes Clinical Pharmacy Subcommittee, Ministry of Health, Malaysia overseeing the DMTAC services in MOH. He graduated with a Bachelor of Pharmacy (Hons) and a Master of Clinical Pharmacy, both from Universiti Kebangsaan Malaysia. He then obtained his Doctor of Philosophy (Ph.D.) from the University of Malaya in the field of pharmacogenomics of antidiabetic therapy. His research area is mainly in the field of diabetes, particularly the clinical response to antidiabetic therapy, the pharmacist's role in diabetes management, and pharmacogenomics. He has presented his research at several international conferences including that of the American Diabetes Association and International Diabetes Federation. Dr. Navin is also among the 20 global recipients of the 'Next Generation Scientist Award 2016' by the University of Basel, Switzerland. He has also received training at the Diabetes Research Program, New York University, the USA in the field of pharmacogenomics of type 2 diabetes. Besides, he was conferred the 'Young Investigator Award' by the National Diabetes Institute of Malaysia in 2009. He has also been appointed as the Advisor for the Practice Transformation Programme – Diabetes by the International Pharmaceutical Federation (FIP) in 2021.

**SP5 Dr Ho Choon Moy, Malaysian Menopause Society
Menopause and Hormone Therapy**

Presentation Synopsis: Menopause is a natural transition signalling the end of a woman's reproductive period, generally occurring between ages 45 and 55. It is defined by the end of menstrual cycles and a significant reduction in the production of ovarian hormones, especially estrogen and progesterone. Hypoestrogenism can lead to a variety of physical and emotional symptoms, including hot flushes, night sweats, mood fluctuations, and an increased risk of osteoporosis and heart disease. Hormone therapy (HT) has been a standard treatment for managing menopausal symptoms and preventing long-term health risks associated with estrogen deficiency. HT primarily involves the administration of estrogen alone or in combination with progesterone. While HT can effectively alleviate vasomotor symptoms, improve mood, and maintain bone density, its use has been controversial due to potential risks if not prescribed appropriately.

Recent advancements in HT include the development of lower-dose regimens and alternative delivery systems, such as transdermal and vaginal preparations, which may reduce systemic side effects. Considering individual risk factors like age, health history, and specific symptomatology, personalised medicine is becoming increasingly important in HT decisions. Non-hormonal alternatives and lifestyle modifications also play a crucial role in managing menopausal symptoms. In conclusion, while HT remains a valuable option for many women experiencing menopause, its application must be carefully tailored to balance benefits and risks. Continuous research and individualized treatment strategies are essential for enhancing outcomes and the quality of life for women experiencing menopause.

Brief CV: Dr Ho Choon Moy is the President of the Asia-Pacific Menopause Federation and the President of the Malaysian Menopause Society. Her journey in healthcare began as a lecturer at the Faculty of Obstetrics and Gynaecology of the National University of Malaysia, and she currently serves at Pantai Hospital Cheras in Kuala Lumpur. She is a Fellow of the Royal College of Obstetricians & Gynaecologists (FRCOG) London. Her other academic qualifications include an MD and a Masters in Obstetrics and Gynaecology from the National University of Malaysia. Her pursuit of knowledge also led her to attain a Masters Science in Antiaging, Aesthetic Med and Regenerative Med, a Fellowship in Minimal Access Surgery, and a Fellowship in Robotic Surgery.

Her dedication to her field is evident in her 35 years of active treatment of menopausal women and her role in helping to run the first menopause clinic in Malaysia. She regularly shares her expertise as a speaker, ensuring that both healthcare professionals and the public are well-informed about menopausal issues. Her contributions extend to the CPG Developmental Group Editorial Board for the Clinical Practice Guidelines on Management of Menopause in Malaysia, published in 2010 and 2022.

In 1994, she was honoured with the Kesatria Setia DiRaja (KSD) award from the Yang DiPertuan Agong for her medical services. She received the Great Women of Our Time award in 2010 and the Successful Women Award in 2013, both in the field of Health and Wellness.

**P5 Professor Dr Wong Tin Wui, UiTM
Pharmacy and Innovation**

Presentation Synopsis: Innovation is a process of bringing new ideas, methods, products, services or solutions that positively resolve a challenge or bring significant values. It involves the development of creative concepts into tangible outcomes to improve the existing conditions. Innovation represents a critical backbone to economic growth, social progress, improved quality of life and sustainable development. The key management to innovation involves opportunity identification, idea creation, development and testing, implementation and scaling, monitor and evaluate, and continuous modification. Exponential change in innovation advancement is an accelerating disruption to the pharmacy healthcare industry. Pharmacists today need to embrace technology and service innovation to meet the patient/consumer expectation, adapting value-based model instead of fee-for-service reimbursement model. Further, pharmacists ideally should be equipped with the capacity to innovate and realise the translational process. This presentation will highlight recent innovative ideas that have been developed to better the future pharmacy services and their rationales to be innovated.

Brief CV: Professor Dr Wong Tin Wui obtained his PhD degree from the National University of Singapore in 1999. He is presently the lecturer and principal fellow at the Faculty of Pharmacy and Smart Manufacturing Research Institute, Universiti Teknologi MARA. His research areas are primarily focused on precision oral, skin and pulmonary nanodrug delivery. He has published over 135 peer reviewed articles. He is the editorial board member of Asian Journal of Pharmaceutical Sciences, Associate Editor of Drug Development and Industrial Pharmacy, Drug Design, Development and Therapy, Frontiers in Pharmacology, Technology in Cancer Research and Treatment, and regional editor of Current Drug Delivery. Professor Wong is the founder of Non-Destructive Biomedical and Pharmaceutical Research Centre, Malaysia and Sino-Malaysia Molecular Oncology and Traditional Chinese Medicine Delivery Joint Research Centre, Medical College, Yangzhou University, China. He is the jury for Maurice-Marie Janot Award and Lecture, and founder and chief jury for Malaysia Technology Expo Sustainable Development Goals International Innovation Awards. He serves as the visiting/adjunct/lecture professor of UCSI University, Taylor's University and Universiti Malaya, Malaysia; National University of Singapore; Yangzhou University, China; Nirma University, India and is the fellow of Academy of Sciences Malaysia and postgraduate faculty member of Chulalongkorn University, Thailand.

P6 Jack Shen Lim, Malaysian Pharmacists Society, Malaysia
Advancing Pharmacy using Technology: How can Malaysian Pharmacists Society (MPS) help?

Presentation Synopsis: In the dynamic field of pharmacy, technology is reshaping practices, enhancing patient care, and streamlining operations. This presentation, "Advancing Pharmacy using Technology: How can Malaysian Pharmacists Society (MPS) Help?" explores the pivotal role of the Malaysian Pharmacists Society in driving technological advancements within the pharmacy sector.

We will examine the initiatives and strategies MPS is implementing to foster technology adoption among pharmacists in Malaysia. The presentation will showcase how MPS is advancing pharmacy using technology. The speaker will highlight the successes and challenges faced by Malaysian pharmacists in adopting these technologies. The discussion will also cover how MPS is advocating for supportive policies and regulations, creating a conducive environment for technological innovation in pharmacy practice.

Attendees will gain valuable insights into the future of pharmacy in Malaysia, understanding how MPS's support and initiatives can help pharmacists stay at the forefront of technological advancements. Join us to discover how MPS is shaping the future of pharmacy in Malaysia, ensuring that pharmacists are well-equipped to meet the evolving needs of their patients and the healthcare system.

Brief CV: Lim Jack Shen, an accomplished pharmacist, holds a Bachelor of Pharmacy from Monash University, Parkville Campus, Melbourne (2003). His career spans various leadership roles in the pharmaceutical industry, currently serving as Director of Business Development and IT at Tigas Alliance Sdn. Bhd. since 2020. His previous roles include Pharmacist and AGM Pharmacy at Berjaya Pharmacy Sdn. Bhd. (2016-2020), Head of Pharmacy at Cosway (M) Sdn. Bhd. (2013-2016), and several managerial positions at Berjaya Corporation Berhad and MOH Group of Companies. He has been a dedicated member of the Malaysian Pharmaceutical Society (MPS), holding the position of General Secretary (since 2023), Honorary Treasurer (2018-2023) and serving as a Council Member (2011-2016). He has chaired several MPS committees, including the Health Technology, Devices, and Innovation Chapter, International Liaison Committee, Strategy & Planning Committee, and Constitution Committee. Additionally, he has been actively involved with the Federation of Asian Pharmaceutical Associations (FAPA), serving as Vice-President, Interim President Elect, and Organising Chairperson for the FAPA Congress 2022 in Kuala Lumpur. His contributions extend to the international arena, where he is a member of the International Pharmaceutical Federation (FIP) and has participated in several committees and groups, such as the FIP Service Awards Selection Committee and the FIP Council as a representative for Malaysia. He has also published and presented on various topics, notably the integration of community pharmacy into primary health care during the COVID-19 pandemic, and has been recognized for his work in promoting the pharmacy profession among young pharmacists. His goals include improving the capacity and management of MPS, nurturing future leaders, building professional capacity, and enhancing the public's perception and engagement with pharmacists.

Forum 2 : Prescription of the Future: The Future Pharmacy Ecosystem with EMR & eRx Gateway Integration

1. Dr Jason Tee, Healthcare Information and Management Systems Society (HIMSS)

Brief CV: Dr Jason is a Certified Professional in Healthcare Information Management Systems. With a focus on the Asia Pacific region, Jason offers consultative expertise to healthcare organizations, ensuring their evolving requirements are effectively addressed. At the core of his mission is a commitment to elevate healthcare delivery processes, emphasizing patient safety and care through meaningful integration of technology. He offers a unique blend of medical proficiency and technological acumen during his tenure at GSK Pharmaceutical, Cerner, and Lexmark Healthcare. He excels in bridging the gap between healthcare providers and IT professionals to facilitate improved care through strategic and impactful technological enhancements. During the Covid-19 pandemic, he co-founded a telehealth platform and collaborates with pharmacies to deliver personalized care through customized prescription services, directly to the patient's doorstep.

2. Mr. G Saravanan, Chief Information Officer (CIO), Thomson Hospital

Brief CV: A seasoned Chief Information Officer (CIO) with 24 years of experience and currently spearheading Thomson group's information technology division, managing team on the best processes for healthcare IT excellence. Experienced in IT strategy for the healthcare industry, to ensure that all systems necessary to support its operations and objective, are successful. Worked throughout South East Asia and Middle East in Hospital environment both as client & consultant. Well versed in Healthcare IT 5G strategy, Hospital IT Operations, Hospital Systems, Telemedicine Device eco-systems, Business Processes, Complying with Legal frameworks, Healthcare Data Management, Standards Adoption, Development & Implementation, Project Management, Enterprise Architecture, Infrastructure, Business Architecture, Solution Architecture to software requirements analysis, design, development and software deployment. Certified in Prince2, SNOMED CT, HL7 RIM, ICD 10.

3. Professor Dr Pauline Lai, Professor (Clinical Pharmacy), University Malaya

Brief CV: Dr. Pauline Lai is a distinguished professor in clinical pharmacy at the Department of Primary Care Medicine, Universiti Malaya, Kuala Lumpur, and an adjunct professor in clinical pharmacy at Sunway University. Her research focuses on medication optimization, particularly in osteoporosis, antimicrobial stewardship, and hypertension, as well as deprescribing, e-health, and advance care planning. Dr. [Name] has secured five external grants totaling approximately RM1 million and ten internal grants amounting to around RM570,000, showcasing her research excellence. Her work has resulted in 87 publications, 842 citations, and an H-index of 17, reflecting her significant impact in the field. Her research has practical applications, influencing national healthcare policy and practice. She has co-authored the Clinical Practice Guidelines for Osteoporosis 2022 (3rd ed.), the Advance Care Planning Guideline for the Ministry of Health Malaysia 2023, and the Guidelines on the Disposal of Unused Medicines in Malaysia. These contributions have directly shaped national clinical practices. In her academic role, she has supervised the completion of eight PhD candidates, eight Masters in Medical Science candidates, and fourteen Clinical Masters candidates. She currently supervises four PhD candidates, two Masters in Medical Science candidates, and two Clinical Masters candidates. Her professional engagement includes membership in the FIP Technology Advisory Group and co-chairing the Malaysian Pharmacists Society Health Technology, Devices & Innovation Chapter. She is also a sought-after plenary speaker and discussant at international conferences and provides training for retail pharmacists through industry engagements.